Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib plus chemotherapy for EGFR-mutant NSCLC
NCT01928160Phase 2Withdrawn
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Jun 2014
- Primary completion
- Mar 2015
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by Vanderbilt-Ingram Cancer Center. Planned start Jun 2014; status: withdrawn.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01928160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01928160.